This article first appeared on GuruFocus.
Moderna (NASDAQ:MRNA) and Merck (NYSE:MRK) shares surged Wednesday after their personalized mRNA cancer therapy delivered a pivotal Phase 3 win in melanoma, providing Moderna with one of its strongest validations yet outside vaccines while giving Merck a potentially important way to extend its dominant Keytruda oncology franchise.
Warning! GuruFocus has detected 4 Warning Signs with MRNA.
Is MRNA fairly valued? Test your thesis with our free DCF calculator.
Moderna is best known for its mRNA-based vaccines, but the biotechnology company has spent years trying to prove the platform can work across other diseases. Intismeran autogene, formerly known as V940 or mRNA-4157, is designed specifically around mutations found in an individual patient's tumor, effectively training the immune system to recognize and attack that cancer.
The Phase 3 INTerpath-001 study enrolled roughly 1,100 patients with surgically removed, high-risk stage IIB-IV melanoma. Intismeran combined with Merck's Keytruda met the study's primary endpoint of recurrence-free survival as well as the secondary endpoint of distant metastasis-free survival, producing statistically significant and clinically meaningful improvements over Keytruda alone.
That is particularly important because Keytruda is already a standard treatment in melanoma. Merck generated $31.7 billion from Keytruda and its QLEX formulation in 2025, nearly half of the company's $65 billion in total sales.
The Phase 3 success also reinforces earlier data. At five years, a smaller Phase 2b study showed the combination reduced the risk of recurrence or death by 49% versus Keytruda alone. Merck and Moderna now have eight Phase 2 and Phase 3 studies underway across cancers including melanoma, lung, bladder and kidney cancer.
Moderna shares jumped more than 50% in premarket trading, while Merck gained over 6%.
For Moderna investors, the biggest question now shifts from whether personalized mRNA cancer therapy works to how commercially scalable it can become. Investors should watch the full Phase 3 hazard ratios, overall-survival trends and manufacturing turnaround times when detailed data are presented.
Regulatory filings are the next major catalyst. The therapy already received FDA Breakthrough Therapy designation based on earlier melanoma data, potentially supporting a faster review path.
For Merck, the strategic payoff could be even broader. A successful personalized therapy paired with Keytruda could deepen the franchise and create a new growth layer around a drug that already generated more than $31 billion last year. Results from additional INTerpath trials, particularly in lung cancer, could determine whether Wednesday's win represents a major melanoma product or the beginning of a much larger cancer platform.